The Antitumor Assessment Core provides support for early discovery of effective antitumor agents and therapeutics. The Core provides resources, professional and technical expertise and advisory services related to the evaluation of agents with potential therapeutic activity, and works closely with investigators to establish in vivo mouse models, including Patient Derived Xenograft (PDX) models, for the design and execution of pharmacokinetic, toxicity and in vivo efficacy studies. The Core also determines the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents. As such, the Core provides a major vehicle to facilitate pre-clinical studies, including GLP-compliant safety toxicology studies in support of IND applications, and is a major contributor to the translational mission of the Center. The Core helps investigators to design, plan, and execute their in vivo experiments, prepare animal protocols and grant applications involving animal studies, and analyze and summarize data for publication and for IND reporting. Importantly, the Core acts as a central coordinator for studies involving support from several Core facilities (including Animal Imaging, Comparative Medicine and Pathology, Tissue Procurement Service, Organic Synthesis, Integrated Genomics, Radiochemistry and Molecular Imaging Probes, and Molecular Cytology) so that studies are carried out properly and in a time- and cost-efficient manner.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Creasy, John M; Sadot, Eran; Koerkamp, Bas Groot et al. (2018) Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 163:1238-1244
Cracchiolo, Jennifer R; Patel, Krupa; Migliacci, Jocelyn C et al. (2018) Factors associated with a primary surgical approach for sinonasal squamous cell carcinoma. J Surg Oncol 117:756-764
Simon, Claire S; Hadjantonakis, Anna-Katerina; Schröter, Christian (2018) Making lineage decisions with biological noise: Lessons from the early mouse embryo. Wiley Interdiscip Rev Dev Biol 7:e319
Ghasemiesfe, Mehrnaz; Ravi, Divya; Vali, Marzieh et al. (2018) Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Ann Intern Med 169:106-115
Benedict, Catherine; DuHamel, Katherine; Nelson, Christian J (2018) Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors. Psychooncology 27:691-694
Gao, Song; Stein, Seth; Petre, Elena N et al. (2018) Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. Cardiovasc Intervent Radiol 41:253-259
Perrier, Nancy D; Brierley, James D; Tuttle, R Michael (2018) Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 68:55-63
Jee, David; Yang, Jr-Shiuan; Park, Sun-Mi et al. (2018) Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals. Mol Cell 69:265-278.e6
Mirpuri, Sheena; Gill, Pavan; Ocampo, Alex et al. (2018) Discrimination and Health Among Taxi Drivers in New York and Toronto. J Community Health 43:667-672
Jones, Christopher W; Misemer, Benjamin S; Platts-Mills, Timothy F et al. (2018) Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study. BMJ Open 8:e019831

Showing the most recent 10 out of 8799 publications